Kazuaki Fukushima

Kazuaki Fukushima

Auto-generated profile, based on publicly available information

Kazuaki Fukushima

Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Komagome 3-18-22, Bunkyo-ku, Tokyo 113-8677, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SMSho Miyamoto
Sho Miyamoto
TNTakara Nishiyama
Takara Nishiyama
AUAkira Ueno
Akira Ueno
HPHyeongki Park
Hyeongki Park
TKTakayuki Kanno
Takayuki Kanno
TSTadaki Suzuki
Tadaki Suzuki
Infectious virus shedding from individuals infected with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is used to estimate human-to-human transmission risk. Control of SARS-CoV-2 transmission requires identifying the immune correlates that protect infectious virus shedding. Mucosal immunity prevents infection by SARS-CoV-2, which replicates in the respiratory epithelium and spreads rapidly to other hosts. However, whether mucosal immunity prevents the shedding of the infectious virus in SARS-CoV-2-infected individuals is unknown. We examined the relationship between viral RNA shedding dynamics, duration of infectious virus shedding, and mucosal antibody responses during SARS-CoV-2 infection. Anti-spike secretory IgA antibodies (S-IgA) reduced viral RNA load and infectivity more than anti-spike IgG/IgA antibodies in infected nasopharyngeal samples. Compared with the IgG/IgA response, the anti-spike S-IgA post-infection responses affected the viral RNA shedding dynamics and predicted the duration of infectious virus shedding regardless of the immune history. These findings highlight the importance of anti-spike S-IgA responses in individuals infected with SARS-CoV-2 for preventing infectious virus shedding and SARS-CoV-2 transmission. Developing medical countermeasures to shorten S-IgA response time may help control human-to-human transmission of SARS-CoV-2 infection and prevent future respiratory virus pandemics.

1 April 2018 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
KFKazuaki Fukushima
Kazuaki Fukushima
NYNaoki Yanagisawa
Naoki Yanagisawa
KIKoichi Imaoka
Koichi Imaoka
MKMasanobu Kimura
Masanobu Kimura
AIAkifumi Imamura
Akifumi Imamura

1 June 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
SFSho Fujiwara
Sho Fujiwara
MNMikio Nakajima
Mikio Nakajima
RKRichard H. Kaszynski
Richard H. Kaszynski
KFKazuaki Fukushima
Kazuaki Fukushima
MTMasaru Tanaka
Masaru Tanaka
AIAkifumi Imamura
Akifumi Imamura

29 March 2021 in Sexually Transmitted Infections
Verified
Journal Article
Closed access
PDF file
KIKazuhiko Ikeuchi
Kazuhiko Ikeuchi
KFKazuaki Fukushima
Kazuaki Fukushima
MTMasaru Tanaka
Masaru Tanaka
KYKeishiro Yajima
Keishiro Yajima
AIAkifumi Imamura
Akifumi Imamura
Objectives: Intramuscular benzathine penicillin G is not available in certain countries. In a previous report, 3 g/day amoxicillin with probenecid was shown to be effective in treating syphilis in patients with HIV; however, 7.3% of patients changed their therapy owing to adverse events. The objective of this study was to assess the clinical efficacy and tolerability of 1.5 g/day amoxicillin without probenecid for the treatment of syphilis.Methods: The routine clinical records of patients diagnosed with syphilis and treated with 1.5 g/day amoxicillin at a tertiary care hospital between 2006 and 2018 were retrospectively analysed. Syphilis was diagnosed if serum rapid plasma reagin (RPR) titres were ≥8 RU and the Treponema pallidum latex-agglutination test was positive. Serological cure was defined as a ≥fourfold decrease in the RPR titre within 12 months in symptomatic early syphilis and within 24 months in latent syphilis.Results: Overall, 138 patients (112 with HIV) were analysed. The percentages of primary, secondary, early latent, late latent and latent syphilis of unknown duration were 8.0%, 50.0%, 25.4%, 5.8% and 10.9%, respectively. The median treatment duration was 4.5 weeks (IQR 4–8 weeks), which was not related to the stage of syphilis. Two patients (1.5%) changed treatment due to skin rash. The rate of serological cure was 94.9% (131/138; 95% CI 89.8% to 97.9%) overall; 93.8% (105/112; 95% CI 87.5% to 97.5%) in patients with HIV and 100% (26/26; 95% CI 86.8% to 100%) in patients without HIV. Treatment duration was not related to the treatment efficacy.Conclusion: The regimen of 1.5 g/day amoxicillin without probenecid is highly effective with a low switch rate in patients with and without HIV.

7 June 2024 in medRxiv
Verified
Preprint
Open access
PDF file
NONobumasa Okumura
Nobumasa Okumura
EMEriko Morino
Eriko Morino
HNHidetoshi Nomoto
Hidetoshi Nomoto
MYMashiho Yanagi
Mashiho Yanagi
KTKozue Takahashi
Kozue Takahashi
MUMugen Ujiie
Mugen Ujiie
Background: The incidence of mpox cases has surged outside endemic regions since May 2022. However, data regarding the safety and efficacy of the LC16m8 vaccine are limited. This study provided opportunities for LC16m8 pre-exposure prophylaxis to high-risk individuals and conducted a randomized controlled trial to assess the effectiveness of LC16m8 in mpox prevention. Methods: This multicenter, randomized, open-label trial enrolled men and women aged ≥18 with high mpox risk. Participants were randomly assigned 1:1 to early or late vaccination groups, receiving vaccinations approximately 70 days apart. Vaccine effectiveness (VE) against mpox development between early and late vaccinations was the primary endpoint. VE against severe mpox, symptoms, “take” incidence, and adverse events were secondary endpoints. Results: A total of 570 and 565 patients were assigned to the early and late vaccination groups, respectively, and 530 and 476 were vaccinated. The median age was 41 years; 99.7% were male, 89.7% were Japanese, and 34.4% had human immunodeficiency virus (HIV). No mpox cases occurred, precluding VE calculations. The take rate was 90.3% (HIV-infected) and 94.6% (uninfected). Adverse events were observed in 97.2% and 98.2% of patients with and without HIV, respectively. No fatal adverse events were observed. Serious adverse events (SAE) were observed in 0.6% (HIV-infected) and 0.5% (uninfected) of patients. One participant without HIV reported pulmonary embolism and deep vein thrombosis as causally undeniable SAE. Local skin reactions: 96.6% (HIV-infected) and 97.9% (uninfected); systemic reactions: 63.6% (HIV-infected) and 64.2% (uninfected). Conclusions: The effectiveness of LC16m8 in mpox remains inconclusive. However, its use in well-controlled HIV-infected and -uninfected individuals showed no significant safety concerns, suggesting the potential for targeted vaccination strategies in at-risk groups. (Japan Registry of Clinical Trials number, jRCT1031230137.)

18 February 2023 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
MSMasahiro Sakaguchi
Masahiro Sakaguchi
YAYuya Atsuta
Yuya Atsuta
NSNoritaka Sekiya
Noritaka Sekiya
YNYuho Najima
Yuho Najima
KFKazuaki Fukushima
Kazuaki Fukushima
NDNoriko Doki
Noriko Doki
Although antipseudomonal agents are administered in high-risk patients, no reports have focused on the risk of carbapenem-resistant (CR) Pseudomonas aeruginosa bacteraemia in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. We retrospectively studied a cohort of adult allo-HSCT recipients with P. aeruginosa bacteraemia, focusing on a comparison between carbapenem-sensitive (CS) and CR P. aeruginosa after initiating conditioning chemotherapy at our institute between January 2005 and December 2020. The incidence, all-cause 30-d mortality of P. aeruginosa bacteraemia, and risk factors for carbapenem resistance among patients with P. aeruginosa bacteraemia in allo-HSCT recipients were evaluated. Forty-eight patients with P. aeruginosa bacteraemia were included, with an incidence of 3.84/100 recipients (CS = 1.92 vs. CR = 1.92). The all-cause 30-d mortality was significantly higher in CR P. aeruginosa bacteraemia (CS = 4.2% vs. CR = 39.1%; P = 0.003). The factor significantly associated with CR P. aeruginosa bacteraemia was carbapenem use for at least 3 d within 30 d before the onset of bacteraemia (odds ratio = 8.92; 95% confidence interval: 1.35-58.90). Inappropriate antimicrobial selection was significantly more frequent in CR P. aeruginosa bacteraemia (CS = 0% vs. CR = 29.2%; P ˂ 0.009). Empirical combination therapy with reference to antimicrobial susceptibility profiles in each institution should be considered when CR P. aeruginosa bacteraemia is suspected in allo-HSCT recipients based on the risk of carbapenem exposure.